This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-13. Anything still debated is marked as such rather than presented as settled.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
from the Pliocene strata of Mininco Formation (Chile), extending known distribution of capybaras west of the Andes. Selvatici et al. (2026) determine a previously unidentified mummified animal from the Homestake Gulch site (Yukon, Canada) as a late Holocene (approximately 3000-years-old) New World porcupine, report the recovery of the first complete ancient mitochondrial genome of a member of this species, and interpret this finding as evidence of appearance of the New World porcupines in the studied area after the appearance of the boreal forest in the aftermath of the Last Glacial Period. Carrillo et al. (2026) study the evolutionary history of caviomorph rodents on the basis of data from extant and extinct members of the group, providing evidence of different trajectories of taxonomic and morphological diversification of Chinchilloidea and Octodontoidea. Evidence from the study of tooth wear of caviomorph rodents from the Paleogene strata of the Shapaja in Peruvian Amazonia, indicative of diverse dietary strategies of the studied rodents, is presented by Robinet et al. (2026). Gutstein et al. (2026) describe fossil material of a member of the genus Cardiatherium from the Bahía Inglesa Formation (Chile), providing evidence of wetter environmental conditions in the area of present-day Pacific coast of the Atacama Desert during the late Miocene. Delinschi et al. (2026) confirm the validity of Sarmatosminthus gabuniai on the basis of the analysis of fossil material from Vallesian sites in Moldova, Romania and Ukraine.
== Epidemiology == A large study found a rate of 29% over a woman's lifetime. Other studies indicate a recurrence rate as low as 3%. In the US, greater than 200,000 surgeries are performed each year for pelvic organ prolapse and 81% of these are to correct cystocele. Cystocele occurs most frequently compared to the prolapse of other pelvic organs and structure. Cystocele is found to be three times as common as vaginal vault prolapse and twice as often as posterior vaginal wall defects. The incidence of cystocele is around 9 per 100 women-years. The highest incidence of symptoms occurs between the ages of 70 and 79 years. Based on population growth statistics, the number of women with prolapse will increase by a minimum of 46% by the year 2050 in the US. Surgery to correct prolapse after hysterectomy is 3.6 per 1,000 women-years.
for molecular models that are more realistic than rigid elastic spheres, such as those incorporating intermolecular attractions. Doing so is necessary to reproduce the correct temperature dependence of
Sources: en.wikipedia.org
== Awards == Gavi was awarded the 2019 Lasker-Bloomberg Public Service Award for "providing sustained access to childhood vaccines around the globe, thus saving millions of lives, and for highlighting the power of immunization to prevent disease". Gavi was nominated for the 2021 Nobel Peace Prize by Norwegian MP Carl-Erik Grimstad. Gavi was awarded the Sunhak Peace Prize in 2022 for promoting vaccine equity at the forefront of COVID-19 by leading COVAX, and for improving global health by increasing access to vaccines for children in vulnerable countries.
=== Brunei === The Royal Brunei Armed Forces uses a 24-hour ration pack that provides a soldier with an entire day's supply of food, plus a limited number of health and hygiene items. Maximum use is made of plastic-foil laminate pouches, and most items can be eaten without further preparation. Currently, four menus are fielded, and all menus are compatible with Muslim dietary restrictions. Example Menu (F): 5 x 170-gram retort pouches (Biriani Chicken, Beef Stir Fry, Sardines in Tomato Sauce, Bubur Jagong/ Corn Porridge, Pineapple Pajeri); plus individual servings of pineapple jam, instant coffee, teabags, sugar, salt, pepper, steminder powder, hot chili sauce, MSG, a multivitamin energy tablet, tissue paper, scouring pad with soap, and matches.
Hedonism about well-being, also called prudential hedonism, holds that pleasure and pain are the only factors of well-being. It states that how well a person's life goes depends entirely on how it feels to live it, expressed as the balance of pleasure over pain. According to this view, a person who experiences frequent joy and contentment has high well-being, whereas someone who is constantly in pain and suffering has low well-being. One view sees pleasure and pain as bodily sensations, like the pleasure of eating delicious food and the pain of injuring a leg. However, hedonists generally take a wider perspective, characterizing pleasure and pain broadly as any experience that feels good or bad. This broader understanding includes the intellectual pleasure of reading an engaging book and the sorrow of losing a loved one. According to quantitative hedonism, the value of each episode of pleasure and pain depends only on its intensity and duration. Qualitative hedonism, an alternative perspective, additionally considers non-quantitative factors, arguing that some pleasures are intrinsically superior to others because of their qualitative character, even if they have the same intensity and duration. One criticism of hedonism acknowledges that some pleasures have value but rejects that this is the case for all of them. According to this view, certain pleasures have no value and may even be bad for a person, such as sadistic pleasures from torturing animals.
Purified animal-sourced insulin was initially the only type of insulin available for experiments and diabetics. John Jacob Abel was the first to produce the crystallised form in 1926. Evidence of the protein nature was first given by Michael Somogyi, Edward A. Doisy, and Philip A. Shaffer in 1924. It was fully proven when Hans Jensen and Earl A. Evans Jr. isolated the amino acids phenylalanine and proline in 1935. The amino acid structure of insulin was first characterized in 1951 by Frederick Sanger, and the first synthetic insulin was produced simultaneously in the labs of Panayotis Katsoyannis at the University of Pittsburgh and Helmut Zahn at RWTH Aachen University in the mid-1960s. Synthetic crystalline bovine insulin was achieved by Chinese researchers in 1965. The complete 3-dimensional structure of insulin was determined by X-ray crystallography in Dorothy Hodgkin's laboratory in 1969. Hans E. Weber discovered preproinsulin while working as a research fellow at the University of California Los Angeles in 1974. In 1973–1974, Weber learned the techniques of how to isolate, purify, and translate messenger RNA. To further investigate insulin, he obtained pancreatic tissues from a slaughterhouse in Los Angeles and then later from animal stock at UCLA. He isolated and purified total messenger RNA from pancreatic islet cells which was then translated in oocytes from Xenopus laevis and precipitated using anti-insulin antibodies.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.